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Thymidylate synthase (TS) is a tumor-associated-enzyme
crucial for DNA replication and inhibited by 5′-fluoroura-
cil. TSPP is a previously characterized anticancer poly-
epitope peptide vaccine to TS (Correale P, JNCI 2005
97:1437). TSPP/VAC-1 is a three-arm dose-finding Phase-
Ib trial aimed to test in pretreated-advanced cancer
patients, TSPP-vaccination alone (arm A), together with
GM-CSF and low dose Aldesleukine (arm B), or together
with chemo-immunotherapy according to the GOLFIG
regimen (Correale P, JCO, 2005, 23:8950) (arm C). TSPP
resulted safe, its MTD was not achieved, while its most-
effective-biological-dose was 300µg. As the most promis-
ing antitumor effects of TSPP were observed in colo-rectal
cancer (mCRC) patients (Cusi MG, CIIT, 2015, epub), we
decided of carrying-out a new study to evaluate in this
subset of patients, the potential ability of a predefined
panel of markers to predict their antitumor response to
TSPP. We thus evaluated41 mCRC patients, 20 males and
21 females, with a good performance status, enrolled
between May 2011 and Jan 2013. Our parameters were
correlated with progression free survival (PFS) and overall
survival (OS) by performing a Kaplan Meier analysis. The
baseline marker values were divided in two groups accord-
ing to their median values, while the changes relative to
baseline values (post-treatment values) were divided
according to a fold ratio ≤ or >1. Patients' PFS and OS
were 6.9 and 11.3 months, respectively; there were no
significant differences in PFS and OS correlated with treat-
ment arm (A vs. B vs. C), number and type of previous
treatments, sex, age, TS expression, HLA2.1 haplotype or
expression of peripheral CTLs, regulatory-T cells, central-
and effector-memory-T cells. Patients bearing K-ras muta-
tions, showed a trend to a shorter PFS (p:0.051) and no
differences in OS (p=0.16). Patients' outcome was instead,
inversely correlated with performance status (ECOG 0-1
vs. 2; PFS, p1, OS, p:0.039). These results suggest that
inflammatory status and autoimmunity may affect TSPP
antitumor activity in mCRC patients. These results deserve
to be considered for the design of new studies.
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